drugset

drugset / Trial / NCT00823407

Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

NCT00823407 ↗

Completed 12 enrolled California Pacific Medical Center Research Institute National Institute on Drug Abuse (NIDA) · collab University of California, San Francisco · collab

RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.

Timeline

Start: 2009-01
Primary completion: 2009-07
Completion: 2009-07

Publications

Results Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010 Dec 2;5(12):e14074. doi: 10.1371/journal.pone.0014074.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	3,4-methylenedioxyamphetamine	Unknown	1.4 mg/kg	Oral

Indications

No indication recorded.